Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation in the joints and can eventually damage cartilage and bone. When conventional medications do not adequately control disease activity, biologic therapies may be considered. These medications target specific parts of the immune system involved in RA inflammation. T-cell costimulation modulators work through different immune pathways to reduce inflammation and protect joint function. Careful screening, individualized medication selection, and regular monitoring are important for maximizing treatment benefits while managing potential risks.
Biologic disease-modifying antirheumatic drugs (DMARDs) are medicines produced using biological processes. Unlike traditional medications that affect broader immune pathways, biologics target specific molecules or immune cells involved in inflammation.
They may help:
Biologics are generally prescribed when disease remains active despite appropriate conventional DMARD treatment or when certain clinical factors make them appropriate earlier.
Several classes of biologic therapies are used to treat rheumatoid arthritis.
Tumor necrosis factor (TNF) is an inflammatory protein involved in RA.
TNF inhibitors include:
These medications can substantially reduce inflammation and joint damage in many patients.
Interleukin-6 (IL-6) is another inflammatory signaling protein.
Medications targeting the IL-6 pathway include:
They may be considered when other treatments have not provided adequate disease control.
Some biologics target B cells, which contribute to abnormal immune activity in RA.
Rituximab is an example and may be used in selected patients, particularly when other biologic therapies have been ineffective or are not suitable.
Abatacept works by interfering with communication between immune cells involved in the inflammatory response.
It may help reduce disease activity and slow joint damage.
Depending on the medication, biologics may be administered through:
Some medications are administered at home, while infusion-based treatments are generally given in a medical setting.
The dosing schedule varies considerably among medications.
Many biologics can be used alongside conventional DMARDs such as methotrexate. Combining treatments may improve disease control for some patients.
However, not every biologic needs to be combined with methotrexate, and treatment decisions depend on disease activity, previous medication response, side effects, and other health considerations.
For people with active RA, biologics may:
Response varies from person to person, and sometimes more than one medication must be tried before finding an effective treatment.
Because biologics modify immune activity, they can increase susceptibility to certain infections.
Potential side effects vary by medication but may include:
Certain biologics may also carry specific risks involving the liver, blood counts, cardiovascular system, or other organs.
Healthcare providers commonly evaluate infection risks before starting biologic therapy.
Depending on the medication and individual circumstances, screening may include testing for:
Vaccination status may also be reviewed before treatment begins.
Regular follow-up helps determine whether the biologic is working and whether side effects are developing.
Monitoring may include:
If a biologic stops working or causes significant adverse effects, a rheumatologist may recommend changing treatment.
The choice of biologic depends on several factors, including:
A rheumatologist can determine which treatment approach best fits the individual's circumstances.
Rheumatoid arthritis biologics have significantly expanded treatment possibilities for people with moderate to severe disease. TNF inhibitors, IL-6 inhibitors, B-cell therapies, and T-cell costimulation modulators work through different immune pathways to reduce inflammation and protect joint function